KRYS Krystal Biotech Inc

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: .

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on and (formerly Twitter).

CONTACT

Investors and Media:

Stéphane Paquette, PhD

Krystal Biotech

            



EN
17/04/2025

Underlying

KRYSKrystal Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Krystal Biotech Inc

Free Trial
KRYS Krystal Biotech...

Krystal Biotech Inc: 2 directors

Two Directors at Krystal Biotech Inc sold 14,127 shares at between 150.263USD and 150.273USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...

KRYS KRYSTAL BIOTECH INC
07/11/25 July 11, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB...

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), a 2:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the tr...

July 9, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Tria...

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with full corneal healing by 3 months as well as significant visual acuity improvement from hand motion to 20/25 at 8 months PITTSBURGH, June 24, 2025 (GLOBE NEWSWIRE) --   (the “Company”) (NASDAQ: KRYS) announced t...

June 24, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthc...

Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference PITTSBURGH, June 03, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:00 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 2:00 pm ET on Tuesday, June 10, 2025 and will be posted on the I...

June 3, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at BofA Securities 2025 Health Care Confere...

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 11:20 am PT on Wednesday, May 14, 2025 and will be posted on the Investors section of...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch